Aroa Biosurgery Limited (ASX: ARX)

Market Cap	255.23M
Revenue (ttm)	70.08M
Net Income (ttm)	-6.99M
Shares Out	344.90M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	73.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,200
Average Volume	287,776
Open	0.730
Previous Close	0.740
Day's Range	0.730 - 0.737
52-Week Range	0.440 - 0.815
Beta	0.57
RSI	50.57
Earnings Date	Jan 23, 2025

About Aroa Biosurgery

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that de...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Country: New Zealand
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ARX

Financial Performance

In 2023, Aroa Biosurgery's revenue was 69.07 million, an increase of 9.01% compared to the previous year's 63.36 million. Losses were -10.63 million, 2583.8% more than in 2022.

Financial numbers in NZD